EcoDrugPlus

Tyrosine-Protein Kinase Fyna

Ensembl ID : ENSIPUG00000005468
Gene Symbol: LOC108270342
3 Cross references
191 Possible Orthologues:

Tyrosine-Protein Kinase Receptor Ufo

Ensembl ID : ENSIPUG00000007233
Gene Symbol: LOC108280600
3 Cross references
187 Possible Orthologues:

V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog

Ensembl ID : ENSIPUG00000004259
Gene Symbol: KRAS
4 Cross references
207 Possible Orthologues:

V-Akt Murine Thymoma Viral Oncogene Homolog 1

Ensembl ID : ENSIPUG00000019502
Gene Symbol: AKT1
3 Cross references
212 Possible Orthologues:

V-Akt Murine Thymoma Viral Oncogene Homolog 2

Ensembl ID : ENSIPUG00000001008
Gene Symbol: LOC124626942
3 Cross references
210 Possible Orthologues:

V-Akt Murine Thymoma Viral Oncogene Homolog 3a

Ensembl ID : ENSIPUG00000008940
Gene Symbol: AKT3A
3 Cross references
203 Possible Orthologues:

V-Rel Avian Reticuloendotheliosis Viral Oncogene Homolog A

Ensembl ID : ENSIPUG00000011563
Gene Symbol: RELA
3 Cross references
200 Possible Orthologues:

V-Src Avian Sarcoma (Schmidt-Ruppin A-2) Viral Oncogene Homolog

Ensembl ID : ENSIPUG00000019030
Gene Symbol: SRC
3 Cross references
197 Possible Orthologues:

Vascular Endothelial Growth Factor Aa

Ensembl ID : ENSIPUG00000000895
Gene Symbol: VEGFAA
3 Cross references
181 Possible Orthologues:

Vascular Endothelial Growth Factor Ab

Ensembl ID : ENSIPUG00000017388
Gene Symbol: VEGFAB
3 Cross references
201 Possible Orthologues:

Vitamin D Receptor A

Ensembl ID : ENSIPUG00000000797
Gene Symbol: VDRA
3 Cross references
388 Possible Orthologues:

Vitamin D Receptor B

Ensembl ID : ENSIPUG00000020135
Gene Symbol: VDRB
3 Cross references
392 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).